NCT07784387 A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal
| NCT ID | NCT07784387 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Janssen-Cilag Farmaceutica Ltda. |
| Condition | Urinary Bladder Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2026-08-25 |
| Primary Completion | 2028-02-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2026-08-25 with a primary completion date of 2028-02-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal. HR-NMIBC is an early-stage bladder cancer that is limited to the inner lining of bladder but has a considerable high chance of cancer coming back or worsening.
Eligibility Criteria
Inclusion criteria: * Bladder cancer diagnosis between January 1, 2016 and December 31, 2020 * Tumor stage N0/x and M0/x plus any of the following: Tis (primary CIS); TaG3/HG (high-grade non-invasive papillary carcinoma); or T1 (tumor invading subepithelial connective tissue) * Minimal follow-up time of 5 years unless there is premature death event Exclusion criteria: * Tumor stage at diagnosis classified as TaG1-2, T2-T4, N1-3, or M1 * History of radical cystectomy performed either prior to the HR-NMIBC index diagnosis or for an indication unrelated to the index HR-NMIBC * Participation in any interventional clinical trial during the observation period
Contact & Investigator
Janssen-Cilag Farmaceutica Ltda. Clinical Trial
STUDY DIRECTOR
Janssen-Cilag Farmaceutica Ltda.
Frequently Asked Questions
Who can join the NCT07784387 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Urinary Bladder Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07784387 currently recruiting?
Yes, NCT07784387 is actively recruiting participants. Contact the research team at Participate-In-This-Study1@its.jnj.com for enrollment information.
Where is the NCT07784387 trial being conducted?
This trial is being conducted at Lisbon, Portugal.
Who is sponsoring the NCT07784387 clinical trial?
NCT07784387 is sponsored by Janssen-Cilag Farmaceutica Ltda.. The principal investigator is Janssen-Cilag Farmaceutica Ltda. Clinical Trial at Janssen-Cilag Farmaceutica Ltda.. The trial plans to enroll 250 participants.